argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye DiseaseGlobeNewsWire • 12/15/25
Biotech is back. Here's why these rallying stocks belong in your portfolio now.Market Watch • 11/03/25
argenx Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 10/30/25
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis PatientsGlobeNewsWire • 10/29/25
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific SessionGlobeNewsWire • 10/15/25
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025GlobeNewsWire • 10/03/25
FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing OperationsBusiness Wire • 09/18/25
Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/08/25
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMGGlobeNewsWire • 08/25/25